OTCMKTS:CRPOF Ceapro (CRPOF) Stock Price, News & Analysis $0.17 0.00 (0.00%) As of 06/6/2024 Add Compare Share Share Stock Analysis Stock AnalysisEarnings About Ceapro Stock (OTCMKTS:CRPOF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ceapro alerts:Sign Up Key Stats Today's Range$0.17▼$0.1750-Day Range$0.17▼$0.1752-Week Range$0.11▼$0.40VolumeN/AAverage Volume15,466 shsMarket Capitalization$13.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCeapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.Read More… Remove Ads Receive CRPOF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ceapro and its competitors with MarketBeat's FREE daily newsletter. Email Address CRPOF Stock News HeadlinesAeterna Zentaris and Ceapro Complete Merger TransactionJune 3, 2024 | globenewswire.comCeapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate UpdateMay 29, 2024 | globenewswire.comSilent Raid on IRAs and 401(k)s Begins—Are You Next?Look around—everything feels oddly steady. Gas prices aren't skyrocketing. Banks aren't collapsing. The markets? They're holding up—for now. But if history has taught us anything, it's this: when things feel too quiet, chaos is right around the corner.March 12, 2025 | Genesis Gold Group (Ad)Ceapro Inc. Reports 2023 Financial Results and Operational HighlightsApril 29, 2024 | globenewswire.comAeterna Zentaris Inc: Ceapro Receives Final Court Approval for Merger with Aeterna ZentarisMarch 28, 2024 | finanznachrichten.deCeapro Receives Final Court Approval for Merger with Aeterna ZentarisMarch 28, 2024 | globenewswire.comAeterna Zentaris and Ceapro Merger Approved by Securityholders at Special MeetingsMarch 12, 2024 | globenewswire.comLeading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical CompanyFebruary 26, 2024 | globenewswire.comSee More Headlines CRPOF Stock Analysis - Frequently Asked Questions How have CRPOF shares performed this year? Ceapro's stock was trading at $0.17 at the beginning of 2025. Since then, CRPOF stock has increased by 0.0% and is now trading at $0.17. View the best growth stocks for 2025 here. How do I buy shares of Ceapro? Shares of CRPOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today3/12/2025Next Earnings (Estimated)3/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:CRPOF CIKN/A Webwww.ceapro.com Phone(780) 421-4555Fax780-421-1320EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,490,000.00 Net Margins-69.60% Pretax Margin-31.44% Return on Equity-20.30% Return on Assets-18.07% Debt Debt-to-Equity RatioN/A Current Ratio11.00 Quick Ratio7.72 Sales & Book Value Annual Sales$7.14 million Price / Sales1.86 Cash Flow$0.06 per share Price / Cash Flow2.74 Book Value$0.32 per share Price / Book0.53Miscellaneous Outstanding Shares78,293,000Free FloatN/AMarket Cap$13.31 million OptionableNot Optionable Beta1.47 7 Top Nuclear Stocks To Buy NowNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (OTCMKTS:CRPOF) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersDeFi Coin on Verge of Breakout!We’re Opening the Ultimate Crypto Vault… Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredDOGE’s Next Move: Not what you thinkDonald Trump, Elon Musk and the Department of Government Efficiency have kept their word. Moving even faste...Weiss Ratings | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ceapro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ceapro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.